“In Q1, we made decisive progress across clinical operations and R&D,” said Punit Dhillon, President & CEO of Skye. “Nimacimab continues to demonstrate a differentiated profile as a potential weight loss therapy, with a peripherally restricted mechanism that may set it apart from both GLP-1s and small-molecule CB1 inhibitors. We’re advancing a body of preclinical and clinical evidence that supports its potential in reshaping the treatment landscape in obesity.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKYE:
- Skye Bioscience announces inducement grant under Nasdaq listing rule
- Skye Bioscience announces new preclinical data for nimacimab
- Skye Bioscience’s Positive Earnings Call Highlights Nimacimab Progress
- Skye Bioscience: Strategic Advancements and Robust Financial Health Support Buy Rating
- Skye Bioscience price target lowered to $14 from $18 at Craig-Hallum
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue